Targeting specific-tissue antigens, like prostate-specific membrane antigen (PSMA), may reduce off-tumor toxicity as demonstrated by pasotuxizumab (PSMA × CD3) which has shown a favorable safety profile and early efficacy signs by prostate-specific antigen (PSA) reductions and durable responses in metastatic castration-resistant prostate cancer (mCRPC) [201]. Here, FOLH1 is linked to neoplasm.